Oseltamivir

C. diff Risk

None

Oral Bioavailability

Good (70 to 90%)

Approximate Cost

$5.66/day

Dosing

Immunocompromised or Critically Ill
75mg PO BID x 5 days or longer

Prophylaxis
75mg PO daily

NOTE: 2018 IDSA guidelines recommends initiation of Oseltamavir for

  • Persons of any age who are hospitalized with influenza, regardless of illness duration prior to hospitalization
  • Outpatients of any age with severe or progressive illness, regardless of illness duration

General Information

Common Usage

Treatment and prophylaxis of influenza

Adverse Effects

  • GI upset common

  • Rare - Stevens Johnson

  • Neuropsychiatric side effects reported

Major Interactions

No significant interactions

Tablet/Capsule Strengths

SPECIAL AUTHORIZATION REQUIRED

Additional Information

Higher doses (150mg PO BID) have not been shown to be superior but may be considered in critically ill or obese patients.

EH prescribing restrictions:
None

NLPDP Status
Special Authorization Required

Also available 6 mg/mL liquid for NG administration

Pharmacology

Antimicrobial class: Antiviral - Neuraminidase inhibitor

Pregnancy category: C

Average serum half life: 2 hours

Lung penetration: Therapeutic